Format

Send to

Choose Destination

See 1 citation found using an alternative search:

J Am Soc Nephrol. 2013 Apr;24(5):702-11. doi: 10.1681/ASN.2012070734. Epub 2013 Feb 21.

The treatment of minimal change disease in adults.

Author information

1
Columbia University Medical Center-Internal Medicine, Division of Nephrology, 622 West 168th Street, PH 4-124, New York, NY 10025, USA.

Abstract

Minimal change disease (MCD) is the etiology of 10%-25% of cases of nephrotic syndrome in adults. The mainstay of treatment for adult MCD, oral glucocorticoids, is based on two randomized controlled trials and extensive observational data in adults, and this treatment leads to remission in over 80% of cases. Relapses are common, and some patients become steroid-resistant (SR), steroid-dependent (SD), or frequently relapsing (FR). The data guiding the treatment of these patients are limited. Here, we review MCD in adults with particular focus on the evidence for immunosuppressive therapy in these patients.

PMID:
23431071
DOI:
10.1681/ASN.2012070734
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center